Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard®

Meriter partners with Exact Sciences in effort to get more patients screened for colorectal cancer

MADISON, Wis.(BUSINESS WIRE) Exact Sciences Corp. (NASDAQ: EXAS) today announced that Meriter-UnityPoint Health will now offer Cologuard®, the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer.

Cologuard analyzes a person's stool to detect both altered DNA and blood known to be associated with colorectal cancer and precancer. Cologuard has been proven to find 92 percent of colorectal cancers in average risk patients with 87 percent specificity. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test.

"At Meriter, our patients come first. When we have opportunities to get more people screened for a preventable disease like colon cancer, it's our duty to make that option available to our patients," said Meriter Medical Group President Dr. Robert Turngren. "There's no better screening test than the colonoscopy - and that will always be our first recommendation. But for those who are not willing to have a colonoscopy, this is a non-invasive option to provide them. We're here to prevent illness and save lives."

Colorectal cancer is the second-leading cancer-related cause of death in the United States. It is often considered the most avoidable, yet least prevented cancer due to the lack of patient compliance with current screening options. Most colorectal cancers develop slowly over several years. Unfortunately, 23 million Americans aged 50 and over do not get screened as recommended.

"Meriter's adoption of Cologuard will help expand patient access to this clinically significant cancer screening technology," said Kevin Conroy, President, CEO and Chairman of Exact Sciences. "Compliance with colorectal cancer screening is critical to early detection and potentially prevention. We look forward to working with the healthcare providers at Meriter toward a future where colorectal cancer is identified earlier and survived more often."

Talk to your doctor about your risk for colorectal cancer and which screening option is right for you. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Both false positives and false negatives do occur with Cologuard. Any positive should be followed by a diagnostic colonoscopy.

Available by prescription only.

About Meriter-UnityPoint Health

Meriter-UnityPoint Health provides comprehensive, coordinated care to patients throughout the Greater Madison area through our clinics, hospital and home care services. Employing more than 3,500 people, Meriter offers primary and specialty care, including heart and vascular, orthopedics, women's health, and the busiest birthing center in Wisconsin. Meriter is a 2014 recipient of the National Research Corporations' Top Rated Pediatric Doctors award and a four-time winner of the Most Wired award. For more information, visit meriter.com.

About Exact Sciences Corp.

Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, follow us on Twitter @ExactSciences or find us on Facebook.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, timing of our launch of a commercial product, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Meriter-UnityPoint Health Marketing Manager
Jessika Kasten, 608-516-2256

Source: Exact Sciences Corp. 

News Provided by Acquire Media

Topics: Exact Sciences News

Subscribe To The Blog